Arvinas, Inc. - Common Stock (NQ:ARVN)

7.900 +0.300 (+3.95%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

August 08, 2025

From Arvinas Inc.

Via GlobeNewswire

Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach ↗

August 07, 2025

Via Stocktwits

Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates ↗

August 06, 2025

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Via Chartmill

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

From Arvinas Inc.

Via GlobeNewswire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

What Analysts Are Saying About Arvinas Stock ↗

June 02, 2025

Via Benzinga

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

July 30, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

July 09, 2025

From Arvinas Inc.

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

June 23, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 18, 2025

Via Benzinga

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

June 13, 2025

From Arvinas Inc.

Via GlobeNewswire

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 09, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval ↗

June 06, 2025

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients

Via Benzinga

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

June 06, 2025

From Arvinas Inc.

Via GlobeNewswire

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

From FN Media Group LLC

Via GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

June 05, 2025

From Arvinas Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

June 02, 2025

From Pomerantz LLP

Via GlobeNewswire

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025

From Arvinas Inc.

Via GlobeNewswire

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)

May 28, 2025

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

May 28, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

May 22, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm

May 21, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

May 18, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

May 13, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Arvinas, Inc. on Behalf of Arvinas Stockholders and Encourages Investors to Contact the Firm

May 07, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.